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Abstract
The RNA-binding protein FUS/TLS, mutation in which is causative of the fatal motor neuron 
disease ALS, is demonstrated to directly bind to the U1-snRNP and SMN complexes. ALS-
causative mutations in FUS/TLS are shown to abnormally enhance their interaction with SMN and 
dysregulate its function, including loss of Gems and altered levels of small nuclear RNAs 
(snRNAs). The same mutants are found to have reduced association with U1-snRNP. 
Correspondingly, global RNA analysis reveals a mutant-dependent loss of splicing activity, with 
ALS-linked mutants failing to reverse changes caused by loss of wild-type FUS/TLS. 
Furthermore, a common FUS/TLS mutant-associated RNA splicing signature is identified in ALS 
patient fibroblasts. Taken together, these studies establish potentially converging disease 
mechanisms in ALS and spinal muscular atrophy, with ALS-causative mutants acquiring 
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properties representing both gain (dysregulation of SMN) and loss (reduced RNA processing 
mediated by U1-snRNP) of function.
Introduction
FUS/TLS is an hnRNP protein that contains one RNA recognition motif (RRM) and three 
RGG motifs, the latter of which are presumably used primarily for protein-protein 
interactions. FUS/TLS is predominantly nuclear, but is also known to shuttle between the 
nucleus and cytoplasm. It has been associated with multiple steps in RNA metabolism, 
including transcription, splicing, microRNA (miRNA) processing, mRNA transport and 
local translation1. The discovery of protein aggregates and causative mutations in FUS/
TLS2,3 and TDP-434-7, two strikingly similar RNA binding proteins, as dominant causes of 
both the fatal adult motor neuron disease Amyotrophic Lateral Sclerosis (ALS) and the 
second most frequent degenerative cognitive disorder [frontal temporal degeneration (FTD)] 
has initiated a paradigm shift in research on this pair of diseases, with errors in RNA 
maturation now a focus as a central component of disease mechanism1-8.
Most disease causing mutations are clustered in the FUS/TLS nuclear localization signal 
(NLS) and as expected have been shown to provoke increased cytoplasmic localization of 
the mutant protein9. However, nuclear clearance of FUS/TLS mutants does not always 
accompany its mutation in ALS and FTD patients10. More fundamentally, whether disease 
mechanism is driven by loss of FUS/TLS nuclear function or gain of toxicity is unsettled. 
Genome-wide approaches have identified thousands of RNA targets bound by FUS/TLS in 
vivo11-16, and depletion of it leads to broad misregulation of RNA processing, including 
many mRNAs encoding proteins important for neuronal function11.
Defects in RNA metabolism also have essential roles in the childhood onset motor neuron 
disease spinal muscular atrophy (SMA) caused by deficiency of the SMN protein17. SMN is 
part of a large multi-protein complex that is essential for the biogenesis of small nuclear 
ribonucleoprotein particles (snRNPs)18-20. As core components of the splice comprised of 
snRNAs (U1, U2, U4, U5, U6 for the major spliceosome; U11, U12, U4atac, U5, U6atac for 
the minor spliceosome) and their bound proteins. snRNPs function to define splice sites and 
catalyze RNA splicing reactions21. Prior efforts have reported markedly decreased snRNP 
assembly activity and reduced snRNA levels in SMN-deficient cells22-25, SMA mice24-27 
and SMA patient tissues22,27, thereby producing broadly misregulated RNA splicing24,25.
SMN complexes are primarily localized in the cytoplasm, in intranuclear Gems, and in 
axons of motor neurons28. Loss of Gems is a cellular hallmark in SMA. Both reduction and 
mutation in TDP-43 or SOD1 have been reported in mice to disrupt Gem assembly or 
stabilization29-32. FUS/TLS, too, has been reported to be associated with SMN 
complexes33-35. Gems and axonal distribution of SMN are reduced (about 50% and 20%, 
respectively) in patient fibroblasts or transfected rat cortical neurons with ALS-associated 
mutations in FUS/TLS33,35. Cytosolic mis-localization of FUS/TLS mutants has also been 
shown to increase snRNA accumulation within the cytoplasm36. However, the molecular 
mechanism(s) underlying such changes is not well established.
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Here we determine that FUS/TLS directly binds the SMN protein, with its association 
mediated by the RGG motifs in FUS/TLS and the Tudor domain in SMN. Surprisingly, 
multiple ALS-causative mutations in FUS/TLS increase FUS/TLS interaction with SMN, 
thereby affecting the normal function of SMN by both reducing Gem bodies and changing 
steady state levels of some snRNAs in transgenic mouse tissues, and patient fibroblasts 
expressing mutant FUS/TLS. Furthermore, FUS/TLS is found to interact with U1 snRNP 
complexes, with ALS-causative mutations shown to reduce this binding. Global analysis of 
RNA splicing reveals that mutant FUS/TLS-dependent splicing changes mimic partial 
FUS/TLS loss of activity, independent of cytosolic mis-localization. A common RNA 
splicing signature is identified in patient fibroblasts carrying different FUS/TLS mutations, 
with many changes overlapping ones induced by reducing either FUS/TLS or SMN. These 
results provide evidence for both gain and loss of function caused by ALS-linked mutations 
in FUS/TLS and the potential convergence in pathological pathways of ALS and SMA.
Results
Identification of a FUS/TLS protein interaction network
We sought to comprehensively determine FUS/TLS-associated proteins by combining 
tandem affinity purification with quantitative mass spectrometric analysis using stable 
isotope labeling by amino acids in cell culture (SILAC)37 (Fig. 1). FUS/TLS was triply 
tagged, including a localization-affinity purification (LAP)-tag (comprised of GFP and hexa-
histidine tags for visualization and purification) and an additional amino-terminal HA 
[YPYDVPDYA] tag (Fig. 1a). A HeLa cell line stably expressing a single copy of LAP-
tagged FUS/TLS was generated using a site-directed recombinase (Flip). Epitope-tagged 
human FUS/TLS accumulated to a level equivalent to endogenous FUS/TLS in the parental 
cells, with a corresponding reduction in untagged endogenous FUS/TLS to about half its 
initial level, presumably through autoregulation (Fig. 1b)11,38. Tagged wild-type FUS/TLS 
accumulated within nuclei in a pattern indistinguishable from endogenous FUS/TLS (Fig. 
1c).
To identify specific interactors, even those in low abundance while eliminating abundant 
contaminant proteins, cell lines stably expressing the LAP tag-containing wild-type 
FUS/TLS were grown in isotopically “heavy” medium containing 13C6, 15N4-arginine 
and 13C6, 15N2-lysine, while the parental line (i.e., no transgene) was grown in “light” 
medium containing normal arginine and lysine (Fig. 1d). Compared to the parental cells, the 
first prescission cleavage eluates after GFP immunoprecipitation and final eluates after His-
tag affinity chromatography of extracts from cells expressing the tagged wild-type human 
FUS/TLS contained at least 11 and 17, respectively, additional polypeptides that were 
observable directly with silver staining (marked with dashed lines, Fig. 1e,f).
Quantitative mass spectrometry was used to identify these FUS/TLS-associated proteins. 
The criteria for protein identification included 1) a calculated False Discovery Rate (FDR)39 
below 1%, 2) all the proteins must have been identified with more than two unique peptides, 
and 3) all peptide signals (heavy/light isotope labeling) for each protein must have at least 4-
fold enrichment in FUS/TLS immunoprecipitates compared to the LAP control (purified 
from the parental HeLa cell line). With these criteria, the FUS/TLS interactome was found 
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to be comprised of 35 proteins (Fig. 1g,h). All of these are proteins involved in RNA 
processing: a) associated components of the U1-snRNP and SMN complexes, b) known 
splicing factors (SFSR1 and SFSR3), c) other ALS-linked RNA binding proteins (EWSR1, 
TAF15 and TDP-43), d) associated with polyadenylation (CPSF-160 [cleavage and 
polyadenylation specific factor 1, 160 KDa] and PABPC1 [cytoplasmic poly(A) binding 
protein 1]), and e) components of the Drosha microprocessing complex (DDX3, DDX5, 
DDX17 and hnRNP-U1-like protein) essential for microRNA biogenesis. Using 
immunoblotting, components of U1-snRNP (U1-70K, U1-A, U1-C, sm-B/D), SMN (Gemin 
5 and SMN), and polyadenylation (CPSF-160, and PABP) were confirmed to be selectively 
present in the FUS/TLS affinity purified fraction of the LAP-tagged FUS/TLS expressing 
cell extracts (Fig. 1i). The complete list of FUS/TLS immunoprecipitated proteins is 
presented in Supplementary Table 1.
FUS/TLS interacts with SMN in cells and mouse tissues
To further test the association between FUS/TLS and SMN, endogenous FUS/TLS was 
immunoprecipitated from extracts of HeLa cells and mouse neuroblastoma (N2a) cells either 
undifferentiated or five days after differentiation into a neuron-like morphology. In each 
case, a proportion of SMN co-precipitated with FUS/TLS, with an enhanced interaction in 
the neuron-like cells independent of differentiation status (Fig. 2a). Similarly, FUS/TLS was 
found complexed with SMN in multiple mouse tissues, with comparable co-precipitation 
with SMN in liver, brain and spinal cord extracts (Supplementary Fig. 1a). The 
immunoprecipitation was specific to FUS/TLS interacting proteins, as an unrelated protein, 
GAPDH, was not co-purified (Supplementary Fig. 1b).
Wild-type FUS/TLS is predominantly nuclear, as demonstrated by immunoblotting of equal 
proportions of nuclear and cytoplasmic fractions (Fig. 2b), but is thought to shuttle between 
nucleus and cytoplasm40. In both fibroblasts and neuroblastoma cells, endogenous SMN was 
primarily cytoplasmic, diffusely found throughout the cytoplasm in addition to accumulation 
in bright intranuclear foci (Gems) (Supplementary Fig. 1c). Immunoprecipitation from 
nuclear and cytoplasmic extracts from N2a cells revealed that wild-type FUS/TLS 
associated almost exclusively with nuclear, not cytoplasmic, SMN (Fig. 2b).
The RGG and Tudor domains are essential for the interaction
Methylated arginines in RGG motifs are recognized by Tudor domains, a ~60-amino acid 
structure proposed to facilitate protein-protein interactions involved in several RNA 
processing pathways41. Since SMN contains a single Tudor domain and interacts with 
several RG-containing proteins, including Ewing’s sarcoma protein (EWS) [a homologue of 
FUS/TLS42], we tested whether the RGG motifs of FUS/TLS mediate the association with 
SMN. Deletion mutants of FUS/TLS (Fig. 2c) and SMN (Fig. 2e) were generated to identify 
which domain(s) mediate their interaction. FLAG-tagged FUS/TLS and HA-tagged SMN 
were expressed in HeLa cells using DNA transfection, extracts were prepared, FUS/TLS-
containing complexes were recovered with FLAG antibody, and finally any co-purified 
SMN was detected with an HA antibody. While deletion of a single RGG motif from 
FUS/TLS was insufficient to eliminate co-precipitation of SMN, deletion of all three RGG 
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motifs (producing ΔRGG123) abolished complex assembly containing both FUS/TLS and 
SMN (Fig. 2d).
However, because the decreased association of the ΔRGG123 mutant with SMN also 
correlated with its mislocalization in the cytoplasm (Supplementary Fig. 1d) and the normal 
interaction is found predominantly intranuclearly (Fig. 2b), we then deleted the NLS 
sequences (at the FUS/TLS C-terminus) but kept the RGG motifs intact (Fig. 2c) so as to 
test whether loss of interaction was influenced by cytosolic mis-localization of FUS/TLS. 
ΔNLS and ΔRGG123 mutants distributed cytoplasmically in similar patterns 
(Supplementary Fig. 1d). The ΔNLS mutant associated with a substantially higher 
proportion of SMN than did wild-type FUS/TLS (Fig. 2d), implicating an increased 
cytoplasmic concentration driving an enhanced, cytosolic interaction with SMN. FUS/TLS 
remained complexed to SMN even when its RNA recognition motif (RRM) was deleted 
(Fig. 2d). The Tudor domain of SMN was essential for this interaction, as SMN was no 
longer co-immunoprecipitated with FUS/TLS when the Tudor domain was deleted (Fig. 2f).
Incubation of purified recombinant GST-tagged FUS/TLS protein with 35S-labeled 
FUS/TLS or SMN protein synthesized by coupled in vitro transcription and translation 
demonstrated that GST-FUS bound to itself or to wild-type SMN. GST alone bound neither, 
as expected. The Tudor domain in SMN was required for binding to FUS/TLS (Fig. 2g). 
Incubation of purified His-tagged recombinant SMN with purified recombinant GST, GST-
tagged FUS/TLS, or GST-tagged TDP43 revealed that GST-FUS, but not GST or GST-
TDP43, bound SMN directly (Fig. 2h). RNase treatment of N2a cell lysates eliminated co-
immunoprecipitation (Supplementary Fig. 1e), supporting an RNA-mediated enhancement 
of FUS/TLS interaction with SMN.
Mutants in FUS alter interaction with SMN and reduce Gems
FUS/TLS causative mutations in ALS cluster in two locations. Most lie in the NLS sequence 
at the C-terminus, with most of the others within the RGG motifs 8. Deletions within either 
region affect the association with SMN (Fig. 2). To test how ALS-linked mutations in 
FUS/TLS affected its association with SMN, we co-transfected HeLa cells with genes 
encoding FLAG-tagged, wild-type or mutant FUS/TLS and HA-tagged SMN. FUS/TLS 
immunoprecipitates revealed that five of six mutations in the NLS (except R521H) increased 
binding to SMN (Fig. 3a, lanes 5-10), while mutants within the RGG motifs had the 
opposite effect (Fig. 3a, lanes 3,4). The most dramatic increase in SMN binding was induced 
by the truncation mutant R495X, which lacks the complete NLS sequence.
We then used HeLa cell lines with an integrated single copy, tetracycline inducible wild-
type or mutant-GFP tagged FUS/TLS gene. Induction produced levels 2-3 times of 
endogenous FUS/TLS (Fig. 3b). The truncation mutant R495X was mislocalized, with a 
clearly identifiable presence in the cytoplasm (Fig. 3c and Supplementary Fig. 2). Relative 
to wild-type FUS/TLS, mutation in the NLS (R495X) produced ~3 fold increased binding 
between exogenously expressed FUS/TLS and endogenous SMN (using GFP 
immunoprecipitation) (Fig. 3b), confirming at nearly physiological levels of accumulation 
what was previously seen with higher levels (Fig. 3a). Analysis of immunostaining with an 
SMN antibody revealed that in cells expressing a wild-type FUS/TLS transgene, the number 
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of nuclear Gems was unchanged relative to cells without a transgene. However, 
accompanying its cytosolic mis-localization, expression of ALS-linked R495X mutant 
strikingly reduced nuclear Gems (Fig. 3c; quantified in 3d).
To test the possibility that the loss of nuclear Gems was mediated by mutant FUS/TLS 
sequestering SMN in the cytoplasm, FUS/TLS variant R495X was induced and the cells 
fractionated into nuclear and cytoplasmic components. Cytosolic GAPDH and nuclear 
histone H3 confirmed the fractionation purity (Fig. 3e). Both endogenous and transgenic 
wild-type FUS/TLS were mainly nuclear, butône third of the R495X mutant was 
cytoplasmic (Fig. 3e). An increased proportion of SMN was relocalized to the cytoplasm in 
the presence of FUS/TLS R495X (Fig. 3e), consistent with mis-localization of FUS/TLS 
altering the distribution of SMN and thereby affecting Gem assembly/stability in the 
nucleus. Note, however, that while Gem reduction was a common property of all tested 
ALS-linked FUS/TLS mutants, cytoplasmic redistribution of FUS/TLS was not essential, as 
it was also seen upon accumulation of the almost exclusively nuclear R514G (Fig. 3c,d and 
Supplementary Fig. 2). It is possible the abnormal interaction of mutant FUS/TLS with 
SMN affects overall SMN dynamics within nuclei.
Reduction of Gems and altered snRNAs in patient fibroblasts
We next examined Gem formation in ALS patient fibroblast lines carrying FUS/TLS 
mutations. In lines with R521G or H517Q mutations, Gem numbers per cell were modestly 
reduced relative to control cell lines from three different individuals (Fig. 4a,b), albeit there 
was no obvious increase in cytoplasmic accumulation of FUS/TLS (Supplementary Fig. 3). 
In contrast, the frame shift mutation (M511Nfs*6) that leads to deletion of the NLS was 
diffusely localized in both the cytoplasm and nucleus and Gem bodies were dramatically 
reduced (Fig 4a, b), consistent with our findings in HeLa cells that the FUS/TLS NLS 
truncation mutant had the most severe phenotype (Fig. 3, comparable to the R495X 
mutation).
The SMN complex has been well established to act in the cytoplasm as a chaperone 
catalyzing assembly of snRNPs, essential components of the spliceosome18. SMN 
deficiency is known to severely decrease snRNP assembly capacity and cause profound 
alterations on snRNA levels24,27, although the extent of changes in different snRNAs varies 
in different cell types and tissues of SMA patients24,27. The nuclear function of Gems is not 
clear, beyond some evidence for partial (and dynamic) association with Cajal bodies43-45, a 
nuclear structure involved in snRNP maturation and recycling46. To test whether ALS-
causing FUS/TLS mutants affected snRNP metabolism, we compared the snRNA levels in 
ALS patient fibroblasts harboring FUS/TLS mutations with levels in normal control 
fibroblasts. Although variations were found among the lines with different mutations, 
quantitative RT-PCR measurement revealed a trend for reduced snRNAs of both major and 
minor classes in the patient-derived cells with the exception of R521G, which increased 
several snRNAs of the major class, particularly U4, accompanied by reduced snRNAs in the 
minor class (Fig. 4c).
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Reduction of Gems and altered snRNAs in FUS transgenic mice
To further determine whether a decrease in Gem bodies is a common and relevant feature in 
FUS/TLS-mediated toxicity in vivo, we examined two different sets of FUS/TLS transgenic 
mouse models that develop age-dependent loss of lower motor neurons. The first set of 
FUS/TLS mice express HA-tagged cDNAs encoding wild-type or either of the two ALS-
linked mutations (R514G and R521C) in human FUS/TLS that are transcribed from a mouse 
prion-promoter [to be reported in detail elsewhere]. Co-labeling for the motor neuron marker 
choline acetyl-transferase (ChAT) and for SMN revealed that at 1-month of age, an age prior 
to development of pathology or abnormal motor phenotypes, expression of mutant R521C 
had already provoked a slight reduction of Gems (Fig. 4d-f). By 12-months of age, all 
transgenic lines had developed abnormal motor symptoms with about 25% denervation and 
α motor neuron loss, and this was accompanied by 40-50% reduction in Gems in motor 
neurons (Fig. 4f; p = 0.03, 0.05, 0.04 for R521C, R514G, and wild-type, respectively). Thus, 
in all of these transgenic mouse lines there is age-dependent loss of Gems that correlates 
with appearance of symptoms (Fig. 4f).
Analysis of an additional FUS/TLS transgenic mouse line (in which a hamster prion 
promoter was used to drive expression of a FLAG-tagged human FUS cDNA with the 
R521C mutation47) Reveal a dramatic reduction (20 fold; p = 0.0001) in GEM numbers at a 
symptomatic stage (Supplementary Fig. 4). Furthermore, analysis of snRNA levels revealed 
that U1 and U11 snRNAs were the most reduced (by 40 and 20%, respectively) in the 
mutant transgenic mice compared to non-transgenic littermates (Fig. 4g).
Mutations of FUS/TLS reduce interaction with U1 snRNP
Association of FUS/TLS with U1-snRNP identified earlier by mass spectrometry (Fig. 1g-i) 
was further confirmed by reciprocal immunoprecipitation: GFP-tagged FUS/TLS pulled 
down FLAG-tagged U1-70K and U1-A, and FLAG-tagged U1-70K and U1-A pulled down 
both GFP-tagged and endogenous FUS/TLS (Fig. 5a,b). Similarly, U1-70K and U1-A co-
immunoprecipitated with CPSF-160, a protein involved in 3′-end processing of mRNAs 
(Fig. 5b). U1-C failed to do so in this assay, possibly because the FLAG tag on this small 
(17 kD) protein affected its proper incorporation into the U1 snRNP complex and interaction 
with FUS/TLS. The interaction was RNA dependent, as RNase treatment eliminated co-
immunoprecipitation (Supplementary Fig. 5). Furthermore, FUS/TLS, SMN, CPSF-160 and 
components of U1-snRNP, including U1-70K and U1-A precisely eluted in the same (~1.8 
MKDa) gel permeation chromatography fractions (Fig. 5c). In contrast, PRMT1 (protein 
arginine methyl-transferase 1), another FUS/TLS interactor, migrated together with 
FUS/TLS at fractions corresponding to between 670 KDa and 440 KDa, fractions that did 
not contain U1 components (Fig. 5c).
Next, we determined how ALS-linked mutations in FUS/TLS affected association with U1-
snRNP components, using isogenic cell lines expressing a single copy of LAP-tagged wild-
type and ALS-linked FUS/TLS mutations R495X, R514G, R521G and P525L. While 
similar amounts of U1A and CPSF-160 were co-immunoprecipitated with FUS/TLS for both 
wild-type and each mutant, the association of U1-70K and Sm-B/D (components of Sm 
core) was sharply reduced (by about 5 fold) for the cytoplasmically mislocalized R495X and 
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P525L and the nuclear R521G mutant (Fig. 5d). U1-70K binding was selectively enhanced 5 
fold for R514G. However, the interaction with U1-A was not changed, suggesting that the 
increased binding was not with the whole U1 snRNP complex, which is essential for splice 
site recognition. Since U1 snRNP is also involved in preventing cryptic transcription 
termination48, it is possible the R514G mutant preferentially affects a different aspect of 
FUS/TLS function, such as polyadenylation.
Mutations in FUS/TLS reduce activity on splicing regulation
Since the altered association of FUS/TLS mutants with SMN and U1-snRNP could perturb 
splicing, we next tested if the ALS-linked mutations in FUS/TLS affected alternative 
splicing. After inducing expression of GFP-tagged wild-type or mutant FUS/TLS in HeLa 
cells, endogenous FUS/TLS was reduced by transfection of an siRNA targeting a sequence 
in the 3′UTR of the endogenous FUS/TLS gene but missing from transgenes (Fig. 6a). Both 
wild-type and each of four ALS-causative mutations accumulated to levels comparable to 
the initial level of endogenous FUS/TLS (Fig. 6b). We then compared how many splicing 
events were altered by FUS/TLS depletion and if they were rescued by mutant FUS/TLS. 
For this, we exploited the RNA-mediated oligonucleotide Annealing, Selection, and 
Ligation with Next-Generation sequencing (RASL-seq) method which permits quantitative 
profiling of several thousand selected alternative splicing events in a large number of 
samples 49,50 (Fig. 6c). Our probe library was assembled to assess 5530 unique alternative 
splicing events, most of which were exon inclusion or skipping, with a minority for 
alternative 5′- or 3′-splice sites. Splicing profiling was performed on RNAs from three 
biological replicates in each group. Ratios of shorter to longer isoform counts were 
calculated and used to statistically compare the splicing changes between different groups 
(Fig. 6d).
By comparing the groups of parental HeLa cells with the corresponding cells after reducing 
FUS/TLS, we identified a total of 250 events changed by decrease in FUS/TLS levels, 
including 124 increased long splicing isoforms and 126 enhanced short isoforms (defined by 
t-test with p<0.05 and average fold change >1.5) (Fig. 6d and Supplementary Fig. 6b). 
Inspection of heat maps (produced with hierarchical clustering) revealed that expression of 
tagged wild-type FUS/TLS rescued the majority of splicing events that resulted from 
endogenous FUS/TLS reduction, yielding a pattern more similar to the parental cells (Fig. 
6e). When comparing the groups with RNAi of endogenous FUS/TLS in the presence of 
induced FUS/TLS transgenes to the groups with RNAi only, all ALS-linked mutations were 
found to rescue normal splicing less efficiently than wild-type FUS/TLS (Fig. 6e and 
Supplementary Table 2).
The NLS-truncation mutant R495X, which has the most severe cytosolic mis-localization 
(Supplementary Fig. 6a), failed almost completely to restore any splicing changes arising 
from suppression of endogenous FUS/TLS (Fig. 6e). Another severe NLS mutation (P525L) 
provided modestly better rescue of splicing changes, but was still far less efficient than wild-
type FUS/TLS. Although both R514G and R521G mutants were primarily nuclear with no 
obvious cytoplasmic mis-localization (Supplementary Fig. 6a), they conferred different 
effects on splicing regulation. R514G activity was very similar to wild-type FUS/TLS, while 
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R521G restored fewer splicing events, despite a higher accumulation level than R514G (Fig. 
6b,e). Inspection of scatter plots of rescued fold changes also showed rescue was worst for 
R495X and best for R514G, with the other two mutants in between (Fig. 6f). Multiple 
examples were validated by RT-PCR (Fig. 6g and Supplementary Fig. 6c). Altogether, these 
results demonstrate that ALS-causative mutations in FUS/TLS acquire partial to nearly 
complete loss of normal function in regulating splicing.
Interestingly, we also noticed that many of the splicing targets of FUS/TLS encode RNA-
binding proteins (RBPs), or proteins involved in RNA metabolism (Supplementary Table 3). 
Some splicing changes introduce premature stop codons and presumably induce nonsense 
mediated decay (NMD) of the mRNA (leading to reduced synthesis and function), while 
others modulate protein sequences in important domains (Supplementary Table 3). These 
results indicate that there are probably extensive RNA processing defects in ALS patients 
with FUS/TLS mutations, both arising from direct effects of mutant FUS/TLS and indirect 
effects from altered activity of other RBPs whose levels or properties are changed by mutant 
FUS/TLS.
A global RNA splicing signature in patient fibroblasts
We next tested whether different FUS/TLS mutations conferred a common set of splicing 
changes when expressed from the normal human FUS/TLS locus. For this, we used RASL-
seq to examine splicing alterations in three ALS patient fibroblasts with R521G, H517Q and 
M511Nfs*6 mutations in the FUS/TLS gene, and fibroblasts of three control individuals. 
Hierarchical clustering of short to long ratio for all events showed that the three FUS/TLS 
mutant lines clustered together and had a splicing profile distinct from control lines 
(Supplementary Fig. 7). There were 57 splicing events found to have increased 
accumulation of a long isoform and 53 events have enhanced short isoform (defined by t-test 
p<0.05 and average fold change >1.5) (Fig. 7a and Supplementary Table 4). Inspection of 
heat maps with hierarchical clustering of all these 110 splicing events identified splicing 
patterns common among three different FUS/TLS mutations (Fig. 7b). Several altered 
splicing events were validated using RT-PCR (along with four control individuals) (Fig. 7c), 
supporting a common RNA splicing signature in ALS patient cells with different FUS/TLS 
mutations.
The mutant-dependent splicing alterations could arise from direct effects of compromising 
normal FUS/TLS splicing activity or indirectly through dysregulation of SMN function 
and/or through other RBPs which are targets of FUS/TLS. In order to differentiate these 
effects, we next knocked down either FUS/TLS or SMN in control fibroblasts (Fig. 7d) and 
compared the splicing changes induced by acute loss of FUS/TLS or SMN proteins with 
splicing alterations in mutant FUS/TLS patient fibroblasts. We primarily focused on the 
M511Nfs*6 mutant as it is the most severe mutation. We observed 15 splicing changes 
induced by FUS/TLS knockdown and 8 changes induced by SMN knockdown in control 
fibroblasts that were also seen in M511Nfs*6 mutant cells (Fig. 7e and Supplementary Table 
5). In most cases one or both of the other mutants also had the same trend of alterations (Fig. 
7e and Supplementary Table 5). We also identified another 12 splicing changes induced by 
SMN knockdown that had the opposite changes in FUS/TLS mutants. Three of the latter 
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were regulated in opposite directions by FUS/TLS and SMN, and in this case some 
FUS/TLS mutants produced the same changes as reduction in FUS/TLS while in other 
instances the changes mirrored loss of SMN (Fig. 7e (iv)). The genetic background variation 
and combinatorial effects of different factors in patient fibroblasts which have expressed the 
mutant FUS/TLS for a long time make it difficult to systematically correlate with the effects 
from acute loss of FUS/TLS or SMN protein. Nevertheless, some splicing changes in mutant 
fibroblasts are consistent with the loss of FUS/TLS activity combined with dysregulation of 
SMN function.
Discussion
Combining quantitative mass spectrometry and affinity purification, we have identified 
FUS/TLS to be associated with SMN and U1-snRNP complexes. Remarkably, many NLS-
mutations in FUS/TLS yield an enhanced association with SMN but a reduced binding to 
U1-snRNP, together affecting splicing regulation. Abnormally increased interaction of 
FUS/TLS with SMN might affect its normal nuclear and/or cytoplasmic dynamics and lead 
to Gem body reduction and dysregulation of snRNA levels, a potential common mechanism 
of SMN deficiency in SMA.
SMN complex acts as a chaperone to facilitate snRNP assembly in the cytoplasm18-20. Each 
of the snRNPs contains a unique snRNA and seven common Sm proteins, as well as a set of 
proteins specific to individual snRNAs. This function is mediated by binding of SMN to the 
Sm proteins through its Tudor domain, with the arginine-, glycine-rich (RG) domains on 
SmB, SmD and SmD3. In the nucleus, SMN-containing Gem bodies partially and 
dynamically associate with Cajal bodies mediated by the interaction between SMN’s Tudor 
domain and the RG dipeptide motif in Coilin51, which might be essential for snRNP 
maturation and cycling. Despite the complexity of SMN functions in vivo, snRNP 
metabolism is impaired with SMN deficiency in SMA, and the various snRNA levels are 
also altered to different degrees in different tissues or conditions22,24-27. Our evidence has 
shown FUS/TLS to directly bind SMN, mediated by the three RGG motifs in FUS/TLS and 
the single Tudor domain in SMN, the key motif for interaction with many partners. It is 
possible that the increased binding with mutant FUS/TLS interferes the normal dynamics of 
SMN complex assembly and/or trafficking/cycling, therefore leading to dysregulation of 
SMN function. Furthermore, this disruptive feature might be facilitated by the aggregation-
promoting prion-like feature of FUS/TLS52.
The association of FUS/TLS with U1-snRNP and two other splicing factors, SRSF1 and 
SRSF3, is consistent with the role of FUS/TLS in RNA splicing. Reduction of association 
between FUS/TLS mutants with U1-snRNP suggests a loss of activity in splicing regulation 
by FUS/TLS. The two mutants (P525L and R495X) that were mis-localized in the 
cytoplasm have more severe splicing defects accompanied with their reduced interaction 
with U1 snRNP. Comparing two mainly nuclear mutants (R521G and R514G) with reduced 
and enhanced binding to U1 snRNP, respectively, the reduced interaction of R521G 
correlated with its inability to complement the loss of endogenous FUS/TLS. These findings 
indicate some ALS-linked mutations in FUS/TLS lead to defects in its nuclear function 
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independent of cytosolic redistribution, and strongly suggest the interaction of FUS/TLS 
with U1 snRNP is directly involved in FUS/TLS splicing activity.
It also should be noted that CPSF-160 and PABPC1 are two proteins in the FUS/TLS 
interactome that are involved in 3′-end RNA processing. We further showed that FUS/TLS, 
U1-snRNP and CPSF-160 may indeed form a large complex (~1.8 MDa). This is particular 
intriguing, as the recent work uncovered that U1-snRNP may serve as a governing 
machinery for blocking premature polyadenylation48, suggesting FUS/TLS might play an 
important role in regulating polyadenylation selection. Additionally, three ALS-linked 
genes, EWSR1, TAF-15 and TDP-43, are components of the FUS/TLS interactome. It has 
been previously demonstrated that a small proportion of TDP-43 interacts with FUS/TLS37. 
Interestingly, EWSR1 and TAF-15 co-aggregate with FUS/TLS in FTD patients with FUS 
pathology, but apparently not in ALS patients with FUS mutations53. Determining the 
significance of EWSR1 and TAF-15 association will require further investigation.
Finally, we have identified a common RNA splicing signature profile in ALS patient 
fibroblasts carrying three different mutations in FUS/TLS. Although we previously reported 
splicing changes caused by FUS/TLS depletion in mouse brain11, the differences in species 
and cell types make comparison problematic. We therefore reduced either FUS/TLS or SMN 
in control fibroblasts and compared the corresponding changes to those in mutant FUS/TLS 
fibroblasts. Although there was no expectation that acute loss of function would match that 
from chronic reduction, we still observed several splicing alterations in the mutant 
fibroblasts that showed the same trends as the changes produced by FUS/TLS or SMN 
knockdown. Interestingly, while FUS/TLS mutant-linked splicing changes always showed 
the same direction of changes as in FUS/TLS knockdown conditions, half of the overlaps 
with SMN knockdown occurred in opposite directions, suggesting the effect on SMN 
function might be more complicated than pure loss of activity. Additionally, the disease 
related splicing changes may arise from synergetic effects of direct effects (from reduced 
splicing activity of mutant FUS/TLS and/or its altered recognition of specific pre-mRNA 
substrates) and indirect effects (altered U snRNP metabolism and altered expression levels 
of other RNA-binding proteins which are targets of FUS/TLS).
Taken together, our work has detailed that FUS/TLS interacts with SMN and U1 snRNP 
(Fig. 8). ALS-causative mutations in FUS/TLS affect SMN function as indicated by reduced 
Gem bodies and altered snRNP metabolism, potentially through abnormal interaction of 
SMN with its normal partners and compromised localization, dynamics or function of SMN 
complexes, thereby representing a potential “gain of FUS/TLS toxicity”. The same 
mutations also lead to a reduced activity of FUS/TLS in regulated alternative splicing 
accompanied by a reduced interaction with U1-snRNP, i.e., a “loss of function” effect. Both 
of the “gain” and “loss” properties are independent of obvious cytosolic mis-localization, 
although the defects tend to be worse in mutants with more cytosolic distribution. Abnormal 
copy numbers (one or three copies) of the SMN1 gene have been associated with 
significantly increased risk of sporadic ALS54. Mutations in FUS/TLS (especially ones 
disrupting the NLS) have also been linked recently to Juvenile-onset ALS55,56, a disease 
closer in form to SMA3 (Juvenile SMA, the mildest form of SMA). The collective evidence 
supports a convergent pathological pathway in which defects in RNA metabolism may be 
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central mechanistic components to ALS and SMA, the most prominent motor neuron 
diseases in adults and children, respectively.
Materials and Methods
Plasmids
FUS/TLS cDNA was subcloned into pcDNA-Flag via BamHI and XhoI sites. The RGG1 
(aa 213 to 261), RGG2 (aa 377 to 407), RGG3 (aa 473 to 505), RRM (aa 285 to 370), or 
NLS (aa 514-525) domains were deleted, and ALS-linked point mutations were introduced 
by quick change mutagenesis. SMN was subcloned into pcDNA-HA via BamHI and XhoI 
sites and the Tudor domain (aa 95 to 143) deleted by quick change mutagenesis. FUS/TLS 
was subcloned into pGEX6p-1 using BamHI and SalI sites to generate an N-terminal GST-
fusion tag. The Flp-In LAP-tag constructs based on pcDNA5/FRT/TO were as described37. 
In brief, N-terminal HA-peptide (YPYDVPDYA) tagged FUS/TLS was amplified by PCR 
and inserted into pcDNA5/TO/FRT/LAP using Xho-I and Not-I sites. ALS-linked mutations 
were generated by QuickChange mutagenesis (Stratagene) and confirmed by sequencing the 
entire open reading frame.
Cell culture and transfection
HeLa, N2a and NSC34 cells were grown in DMEM supplemented with 10% (v/v) FBS, 100 
U/ml penicillin and 100 μg ml−1 streptomycin. Primary human fibroblasts (Supplementary 
Table 6) were grown in DMEM supplemented with 20% FBS, 0.1 mM nonessential amino 
acids (Invitrogen), 2 mM L-Glutamine (Invitrogen), and penicillin/streptomycin. For 
differentiation of N2a cells into neuronal-like cells, N2a were cultured in DMEM with 2% 
FBS and 20μM retinoic acid for four days. X-tremeGENE 9 (Roche) was used to transfect 
plasmids; Lipofectamine RNAiMAX (Invitrogen) was used to transfect siRNAs. For 
knockdown experiments, siRNAs were transfected 72 h prior to sample collection. The 
siRNA for FUS/TLS was designed to target the 3′ UTR 
(GACUAUGUAAUUGUAACUAUA). The siRNA for SMN1 was designed to target 
GAAGAAUACUGCAGCUUCCUUAC. ON-TARGETplus Non-Targeting siRNA 
(Dharmacon) was used as a negative control. The isogenic HeLa stable cell lines expressing 
FUS/TLS transgenes were generated as described before37. Transgene expression was 
induced with 4μg/ml tetracycline for 72 h. For replacement experiments, isogenic HeLa cell 
lines were induced with tetracycline overnight prior to siRNA transfection.
Affinity purification and quantitative mass spectrometry
The procedure for TAP-SILAC was performed as before37. Cells were grown in SILAC 
DMEM (Thermo Scientific) supplemented with 10% dialyzed FBS and penicillin/
streptomycin with 0.4 mM of L-arginine and 0.8 mM of L-lysine. Normal (“light”) L-
arginine (69.2 μg ml−1) and L-lysine (116.6 μg ml−1) were added to the “light” growth 
medium, and “heavy” L-Arg-13C6, 15N2.HCl (87.8 μg ml−1), L-Lys-13C6, 15N2.HCl (152 μg 
ml−1) were added for the “heavy” growth medium. For the forward and reverse SILAC, 
stable Flp-In cell lines expressing either wild-type or ALS-linked mutations in FUS/TLS 
were cultured with either light or heavy medium as indicated.
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Immunofluorescence, immunoblotting and antibodies
For HeLa and N2a cells, cells were fixed with 4% (v/v) para-formaldehyde in PBS for 20 
min. Cells were permeabilized in 0.2% (v/v) Triton X-100 for 5 min, blocked in 1% bovine 
serum albumin and 2% donkey serum for 30 min., incubated with primary antibodies for 1 
h, washed with PBS, and finally incubated with FITC- or Cy3-conjugated secondary 
antibodies (Jackson ImmunoResearch). Nuclei were counterstained with DAPI. Cells were 
imaged with a DeltaVision-modified inverted microscope (IX70; Olympus).
For human fibroblasts, cells were fixed with methanol/acetone (1:1) for 15 min, 
permeabilized in 0.1% (v/v) Triton X-100 for 15 min., incubated with primary antibodies 
overnight at 4°C.
The quantification of Gems was represented as average Gem numbers per cell in each cell 
line with three biological replicates. One-way ANOVA was used to assess the variation 
among individual cell lines, showing the variation was not statistically significant within 
control cell lines, while it was comparing controls versus mutants.
For immunoblotting, goat anti-mouse or anti-rabbit IgG HRP-conjugated (GE healthcare) 
was used along with chemiluminescent detection reagents (Thermo Scientific).
The primary antibodies included GAPDH (Cell Signaling, #2118, 1:5000), Flag tag (Sigma, 
F3165, 1:500), HA tag (Novus, NB600-363, 1:1000), FUS/TLS (Bethyl, A300-302A, 
1:5000; Santa Cruz, sc-47711, 1:500), SMN (BD, #610646, 1:5000), U1-70K (Millipore, 
1:2000), U1-A (Abnova, H00006626-D01P, 1:2000), U1-C (Sigma, SAB4200188, 1:1000), 
Sm-B/D (Thermo, MS-450-P0, 1:250), CPSF-160 (Bethyl, A301-580A, 1:5000), PABPC1 
(Santa Cruz, sc-32318, 1:100), GEMIN5 (Bethyl, A301-325A, 1:5000), HSP90 (Stressgen, 
ADI-SPA-846, 1:3000), Histone H3 (Sigma, H0164, 1:5000). The listed concentration was 
used for immunoblotting, and 5-10 fold less diluted for immunofluorescence.
Tissue preparation and procedure for immunohistochemistry was described previously57. In 
brief, anesthetized mice were transcardialy perfused with phosphate buffered saline (PBS), 
followed by 4% paraformaldehyde (PFA) in phosphate buffer for fixation. Spinal cords were 
post-fixed in 4% PFA for 2 hour, cryoprotected in 30% sucrose for over 24 hours and 
embedded in Tissue-Tek. Fixed spinal cords were sectioned at 30μm thickness for staining. 
Antigen retrieval treatment was used for SMN staining, in which tissue sections were 
immersed in in 10 mM sodium citrate (pH 6.0) at 95°C for 15-20 min. Sections were cooled 
down to room temperature and rinsed extensively with PBS before proceeding to 
immunofluorescence staining.
Immunoprecipitation
Dynabeads Protein G were washed twice with Citrate-Phosphate Buffer (CPB; 25 mM citric 
acid, 50 mM Na2HPO4, pH 5.0), and incubated with FUS/TLS antibody for 1 h at room 
temperature. The beads were washed twice in 500 μl CPB, and once in IP lysis buffer (0.3% 
(v/v) NP-40, 200 mM NaCl, 50 mM Tris, pH 7.4, 1 mM DTT, 0.1 mM EDTA, 0.1 mM 
EGTA, with freshly added 1 mM sodium vanadate, 50 mM sodium fluoride and protease-
inhibitor cocktail). Anti-FLAG M2 affinity gel (Sigma, A2220) was used for FLAG IP; 
Sun et al. Page 13
Nat Commun. Author manuscript; available in PMC 2015 July 27.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
GFP-binding for GFP IP35,58. Individual 15-cm plates of HeLa cells were lysed in 1 ml of IP 
lysis buffer, and the DNA sheared by sequential passage through a syringe with 20G, 22G, 
and 26G needles, three times each. The lysates were clarified by centrifugation at 13,000g 
for 20 min at 4 °C. The supernatants were passed through a 0.45-μm filter (Costar). We then 
added 20 μl beads (1:1 suspension) to the cleared lysates and incubated for 4 h at 4 °C. After 
washing five times in lysis buffer, the beads were resuspended in SDS-containing gel 
sample buffer and electrophoresed on an SDS-PAGE gel. For RNase treatment, a nuclease 
cocktail (1 U ml−1 RNase cocktail (Ambion), 500 U ml−1 Benzonase (Novagen) and 2 mM 
MgCl2) was added and incubated on ice for 30 min. For cell fractionation before IP, cells 
were gently lysed (in 20 mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.3% (v/v) NP-40, 
1mM DTT, 0.1 mM EDTA, 0.1 mM EGTA, with freshly added 1 mM sodium vanadate, 50 
mM sodium fluoride and protease-inhibitor cocktail). Nuclei were pelleted at 2300 g for 5 
min at 4 °C, and transferred to a new tube. The nuclei were washed once with the same 
buffer, and re-pelleted, re-suspended in IP lysis buffer. Both nuclear and cytosol fractions 
were clarified at 15000 rpm for 20 min. We adjusted the cytosolic fraction to 200mM NaCl 
and proceeded used for immunoprecipitation.
Recombinant protein purification and GST pull-down assay
GST-tagged recombinant proteins were purified using glutathione sepharose following the 
manufacture’s protocol (GE healthcare). Coupled in vitro transcription and translation 
reactions were used to generate SMN and delta-Tudor SMN proteins with 35S-methione and 
cysteine (Promega). Purified GST and GST-FUS (500 ng) were incubated with SMN and 
delta-Tudor SMN together with 20 μl of glutathione-sepharose at 4°C for 1 hour. The beads 
were subsequently washed three times with wash buffer (50 mM HEPES, pH 7.5, 150 mM 
KCl, 1 mM MgCl2, 0.1% NP-40, 10% glycerol). The associated proteins were eluted with 
15 mM glutathione and analyzed with autoradiography. 6xHis-tag recombinant proteins 
were expressed in bacteria and purified with Ni-NTA (Qiagen) according the manufacturer’s 
manual. In vitro GST-pull-down assay using GST, GST-FUS, and GST-TDP-43 with equal 
amount of recombinant SMN proteins performed as described above. The associated 
proteins were eluted with 15 mM glutathione and analyzed with immunoblots.
Gel filtration chromatography
High-speed supernatant (HSS) from HeLa cells were prepared as described for TAP-SILAC. 
15 mg of HSS is loaded onto Superose 6 column (GE Healthcare) equilibrated in 20 mM 
Tri-HCl, pH 7.4, 50 mM KCl, 1 mM MgCl2. Fractions of 1 ml were collected immediately 
after the void volume and analyzed by immunoblotting as indicated in the figure legend. The 
calibration of the size exclusion column was performed with the following molecular weight 
markers: blue dextran (2 MDa), thyroglobulin (670 KDa), ferritin (440 KDa), aldolase (158 
KDa), and ovalbumin (44 KDa). Peak fractions of the molecular weight markers are 
indicated in Figure 5c.
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RNA isolation, qRT-PCR and RT-PCR
To isolate total RNA from cells or tissues, Trizol (Invitrogen) and treatment with RQ1 
DNase I (Promega) was used. For first-strand cDNA synthesis, random hexamers were used 
with High-capacity cDNA reverse transcription kit (Applied Biosystems).
All qRT-PCR reactions for snRNAs were performed with three biological replicates for each 
group and two technical replicates using the iQ SYBR green supermix (Bio-Rad) on the iQ5 
multicolor real-time PCR detection system (Bio-Rad). The data were analyzed using the iQ5 
optical system software (Bio-Rad; version 2.1). Expression values were normalized to two 
control genes: 5 S rRNA and 5.8 S rRNA. Expression values were expressed as a percentage 
of the average expression of control samples.
Regular RT-PCR (25-30 cycles) was used to validate alternative splicing changes. Isoform 
products were separated on 10% polyacrylamide gels and stained with SYBR gold 
(Invitrogen) and quantified with Image Lab (Bio-Rad). Intensity ratios of long and short 
isoforms were averaged from three biological replicates per group. PCR primer sequences 
are shown in Supplementary Table 7.
For experiments using patient fibroblasts, one-way ANOVA was used to assess variations 
among control and mutant cell lines. Genes with significant variations (p<0.05) were further 
analyzed by post hoc test to determine the pairwise significant changes.
RASL-seq
RASL-seq analysis of splicing switches was carried out as detailed49,50. A pool of 
oligonucleotides was designed to detect 5530 alternative splicing events in human. One 
hundred fmol of RASL-seq oligos were annealed to 1 μg of total RNA isolated from HeLa 
or human fibroblast cells. After ligation, 5 μl eluted ligated oligos was used for 16 ~ 20 
cycles of PCR amplification, and the bar-coded PCR products were sequenced on 
HiSeq2000 with 24-30 samples in one lane. Sequencing data was decoded allowing no 
mismatch with each barcode, and target sequences were mapped with RASL-seq oligo pool 
sequences with Bowtie59 allowing for 1 mismatch. An average of 5 million reads from each 
sample was mapped, with events with less than 4 counts in one of the isoforms removed. 
Ratios of the counts of shorter to longer isoforms were calculated. The significantly changed 
events were identified by t-test and average fold change. Heatmaps were generated by 
hierarchical clustering and TreeView60.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Quantitative proteomic analysis of FUS/TLS using stable isotope labeling by amino 
acids in cell culture (SILAC) coupled with tandem affinity purification (TAP)
(a) Schematic representation of FST/TLS tagging including the localization and affinity 
purification (LAP)-tag composed of GFP followed by PreScission protease cleavage 
sequences, a 6x histidine-tag, and an HA-peptide (YPYDVPDYA). (b) Immunoblotting of 
FUS/TLS showed comparable levels of cell extracts for GFP-tagged or endogenous FUS/
TLS. (c) GFP fluorescence of induced GFP-tagged FUS/TLS and immunofluorescence of 
endogenous FUS/TLS on HeLa Flp-In cells. (d) Schematic representation of TAP 
purification and quantitative analysis using SILAC. (e-f) Silver stain of the samples from the 
PreScission (e) and final (f) elutions of the tandem affinity purification steps. Arrow 
indicates tagged FUS/TLS and * denoted GST-tagged PreScission protease; positions of 
other visible polypeptides are marked with dashes. (g) Graphic representation of FUS/TLS-
interactome. Y-axis displays the average ratio of different peptides per identified protein; the 
X-axis displays protein ID in alphabetical order, with a fourfold enrichment above 
background signal considered to be an FUS/TLS-associated protein (highlighted in colors 
that match identities in (h)). (h) Summary of FUS/TLS associated proteins, identified with 
peptides containing only heavy Lys/Arg and by multiple different peptides from at least two 
independent runs, except *, which denotes the proteins were identified only in one run. The 
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associated proteins were grouped according to the known assigned functions for each. (i) 
Confirmation of putative FUS/TLS associating proteins by immunoblotting, including 
U1-70K, U1-A, U1-C, Sm-B/D, CPSF-160, PABPC1, GEMIN5, SMN.
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Figure 2. FUS/TLS interacts with SMN through RGG motifs and Tudor domain
(a) Immunoprecipitation was carried out from whole-cell lysates of HeLa, undifferentiated 
and differentiated N2a cells using Protein G Dynabeads coated with control IgG or 
FUS/TLS polyclonal antibody. The input and precipitated proteins were immunoblotted with 
FUS/TLS and SMN monoclonal antibodies. (b) N2a cells were fractionated to separate 
nucleus and cytoplasm. FUS/TLS was immunoprecipitated from each fraction, followed by 
immunoblotting with SMN antibody. HSP90 and Histone H3 were used as cytosol and 
nuclear markers respectively. (c) Diagrams of the FLAG-tagged FUS/TLS deletion mutants. 
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(d) HeLa cells were co-transfected with various FLAG-tagged FUS/TLS cDNAs and HA-
tagged SMN construct. Immunoprecipitation was carried out using anti-FLAG M2 beads 
followed by immunoblotting with FLAG and HA antibodies. (e) Diagrams of the HA-tagged 
SMN constructs. (f) HeLa cells were co-transfected with FLAG-tagged FUS/TLS cDNA 
and HA-tagged SMN mutants. Immunoprecipitation/immunoblotting was performed as in 
(d). (g) GST and GST-FUS were expressed and purified from bacteria, separated on SDS-
PAGE, and stained with Coomassie Blue (Left). Purifed GST or GST-FUS was incubated 
with 35S-labeled FUS/TLS, SMN and SMN ΔTudor synthesized by in vitro transcription and 
translation, together with glutathione-sepharose. The associated proteins were analyzed with 
autoradiography. (h) Purified GST, GST-FUS and GST-TDP-43 were separated on SDS-
PAGE and stained with Coomassie Blue (Middle). The three proteins were incubated with 
purified recombinant SMN (bottom) in vitro and GST-complexes affinity purified with 
glutathionine beads, seperated on SDS-PAGE, and immunoblotted with SMN antibody 
(Top).
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Figure 3. ALS-causative mutations of FUS/TLS alter interaction with SMN and reduce Gem 
number
(a) HeLa cells were co-transfected with FLAG-tagged FUS/TLS carrying ALS-linked 
mutations and HA-tagged SMN cDNA, extracts prepared and FUS/TLS immunoprecipitated 
with FLAG antibody, followed by immunoblotting with HA antibody. (b) GFP 
immunoprecipitation from HeLa Flp-In cells expressing GFP-tagged wild-type or R495X 
mutant FUS/TLS, followed by immunoblotting with FUS/TLS (Santa Cruz) or SMN 
antibody. (c) GFP fluorescence and SMN immunofluorescence of HeLa Flp-In cells induced 
to express GFP-tagged wild-type or ALS-linked mutant FUS/TLS. Gems were detected with 
SMN antibody (red spots in nucleus). (d) Quantification of Gem numbers per cell in (c). 
More than 100 cells were counted in each condition. (***p<0.001, one-way ANOVA with 
post hoc test, error bars represent s.d.) (e) HeLa Flp-In cells were induced with tetracycline 
to express GFP-tagged wild-type or R495X FUS/TLS transgenes. Cells were fractionated to 
separate nucleus and cytoplasm. Equal proportion of cell extracts from total, nuclear and 
cytosol fractions were immunoblotted with FUS/TLS, SMN, GAPDH (cytosol marker) and 
histone H3 (nuclear marker) antibodies.
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Figure 4. Reduction of Gems and changes in snRNA levels in ALS patient fibroblasts and 
transgenic mouse spinal cords
(a) Representative images of Gem bodies stained with SMN antibody in human fibroblasts 
from normal or ALS patient carrying FUS/TLS mutations. (b) Quantification of average 
Gem numbers per cell in (a), from three independent experiments. (NSP=0.084 for variance 
among the three control fibroblasts by one-way ANOVA; *p<0.01 and ***p<0.0005 for 
mutants versus controls, one-way ANOVA with post hoc test; error bars represent s.d.) (c) 
qRT-PCR of U snRNAs in normal and patient fibroblast harboring FUS/TLS mutations. The 
Sun et al. Page 24
Nat Commun. Author manuscript; available in PMC 2015 July 27.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
control is the average of three normal fibroblast cell lines. Each condition has three 
biological replicates. The group variance for each gene was analyzed by one-way ANOVA. 
The genes with significant variences (p<0.05) were further analyzed with post hoc test 
comparing mutants versus control (*p<0.05, **p<0.001, error bars represent s.e.m.) (d) 
Immunoblotting of whole spinal cord lysates from transgenic mice with mouse/human 
FUS/TLS antibody. (e) Representative images of Gem bodies in the motor neurons at the 
lumbar section of spinal cord in mice at symptomatic (12-month) stage. Nuclear Gem bodies 
were visualized with SMN antibody and motor neurons were stained with CHAT (choline 
acetyl-transferase) antibody. Left and right panels show representative images from non-
transgenic littermate controls and R521C-FUS expressing transgenic mice. (f) 
Quantification of average Gem numbers per motor neuron in control or transgenic mice 
expressing human wild-type, R514G, or R521C mutations at 1-month and 12-months of age 
with three biological replicates in each group. (*p<0.05, one-way ANOVA with post hoc 
test, error bars represent s.e.m.) (g) qRT-PCR of U snRNAs in spinal cord of mice at 12-
months carrying no transgene, or FUS/TLS wild-type, R514G, R521C mutant transgenes. 
Each condition has three biological replicates. (*p<0.05, one-way ANOVA with post hoc 
test, error bars represent s.e.m.)
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Figure 5. ALS-linked mutations in FUS/TLS reduce its interaction with U1snRNP
(a) Association of FUS/TLS with specific factors of U1-snRNP. FLp-In cells expressing 
wild-type FUS/TLS were transiently transfected with FLAG-tagged U1-70K, U1-A, or U1-
C and immunoprecipiations performed for FUS/TLS or U1-70K, U1-A, or U1-C using 
antibodies to the Lap or FLAG tags, and finally assayed by immunoblotting for FUS or 
FLAG-tagged U1 components. (b) Association of FUS/TLS with U1-snRNP and CPSF-160 
was assayed by immunoprecipitation with FLAG antibodies of extracts from FLAG-tag 
U1-70K or U1-A expressing cells, and then immunoblotted for endogenous FUS/TLS and 
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CPSF-160. (c) Size-exclusion chromatography of extracts of cells transfected as in (a). 
Estimated molecular weights are indicated at the top using blue detran (2 MDa), 
thyroglobulin (670 KDa), ferritin (440 KDa), aldolase (158 KDa), and ovalbumin (44 KDa) 
as marker. Collected fractions were analyzed on SDS-PAGE and immunoblotted with 
CPSF-160, FUS/TLS, U1-70K, U1-A, Sm-B/D, SMN and PRMT1 antibodies. (d) Reduced 
association between U1-snRNP with ALS-linked mutations in FUS/TLS. Extracts of 
isogenic lines expressing different GFP-tagged ALS-linked FUS/TLS mutations were 
immunoprecipiated with GFP antibodies and immunoblotted with antibodies against U1-A, 
U1-70K, Sm-B/D or CPSF-160. Decreased association of U1-70K and Sm-B/D with 
FUS/TLS was apparent in 3 of the 4 NLS-mutations.
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Figure 6. ALS-linked mutations in FUS/TLS reduce its activity in alternative pre-mRNA splicing 
in HeLa cells
(a) Schematic timeline of endogenous FUS/TLS reduction and induction of GFP-tagged 
FUS/TLS, either wild-type or with ALS-mutations, in HeLa Flp-In cells. (b) 
Immunoblotting for FUS/TLS of cell extracts revealed replacement of endogenous 
FUS/TLS (white arrow) with comparable levels of various GFP-tagged FUS/TLS (red 
arrow). (c) Diagram of the RASL-seq methodology. (d) Flow-chart illustrating the 
procedure of RASL-seq analysis and the number of alternative splicing events at each step. 
(e) Heat map with hierarchical clustering of all the 132 wtFUS rescued splicing events in 
groups of parental HeLa cells, cells with FUS/TLS knockdown (FUS RNAi), and 
replacement of endogenous FUS/TLS with GFP-tagged wild-type FUS/TLS (RNAi+WT), 
or R514G mutant FUS/TLS (RNAi+R514G), R521G mutant (RNAi+R521G), P525L 
(RNAi+P525L), or R495X (RNAi+R495X), with three biological replicates in each group. 
(f) Comparisons of rescue activities between various wild-type and mutant FUS/TLS. The 
average fold changes of all the rescued splicing events were calculated by comparing the 
short to long isoform counts ratios in the group of RNAi+WT (or mutants) against the RNAi 
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group. To evaluate how well FUS/TLS mutants rescued the splicing changes compared to 
the wild-type protein, the log2 of fold changes were presented in scatter plots. The dotted 
lines represent values with equal rescue between mutant and wild-type FUS/TLS. Note the 
decreased fold rescue (dots located between X-axis and the dotted line) by 3 of the 4 NLS-
mutaions, consistent with (f). (g) Validation of alternative splicing changes by RT-PCR. 
Quantification of splicing changes is from three biological replicates in each condition. 
*p<0.05, ** p<0.01, *** p<0.001, one-way ANOVA with post hoc test, error bars represent 
s.e.m.
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Figure 7. RNA splicing profiling in human patient fibroblast with FUS/TLS mutations
(a) Flow-chart illustrating the procedure of RASL-seq analysis and the number of alternative 
splicing events at each step. (b) Heat map with hierarchical clustering of 110 alternative 
splicing changes in the three patient fibroblasts with various FUS/TLS mutations compared 
to normal control fibroblasts, with duplicated samples in each cell line. (c) Validation of 
splicing changes by RT-PCR. Quantification for control is from five individual fibroblasts 
with duplicates each, two biological replicates for each FUS/TLS mutant. The group 
variance was analyzed by one-way ANOVA followed by post hoc test determine the 
pairwise significant changes. *p<0.05, ** p<0.01, *** p<0.001, error bars represent s.e.m. 
(d) Normal control fibroblasts were transfected with non-targeting siRNA or siRNA against 
FUS/TLS or SMN1 for three days. Immunoblotting of FUS/TLS and SMN showed the 
knockdown efficiency. GAPDH were blotted as internal control. (e) Comparison of splicing 
changes linked to FUS/TLS mutants with ones induced by FUS/TLS or SMN knockdown. 
Relative short to long isoform ratios were shown from 3-6 biological replicates in each 
condition. *p<0.05, ** p<0.005, *** p<0.0005, one-way ANOVA with post hoc test, error 
bars represent s.e.m.
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Figure 8. Diagram for molecular mechanisms underlying gain- and loss-of RNA processing 
functions by ALS-causative mutations in FUS/TLS
ALS-causative mutations in FUS/TLS enhance interaction with SMN, potentially 
sequestering SMN from its normal localization and function, thereby reducing Gem bodies, 
affecting snRNP assembly, and therefore affecting downstream RNA processing, a “gain of 
toxicity”. The same mutations also decrease FUS/TLS interaction with U1 snRNP, which 
leads to reduced activity of FUS/TLS in mediating alternative splicing, a “loss of function” 
effect similar to loss of wild-type FUS/TLS.
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